Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 11Terminated 4Recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 16Glioblastoma 8Ovarian Neoplasms 7Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Pancreatic Neoplasms 5Rectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Neoplasms 2Melanoma 2Liver Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Rectal Cancer Patients 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Peritoneal Neoplasms 1Optic Nerve Diseases 1

Interventions

Radiotherapy 5Gemcitabine 4Cyclophosphamide 4pazopanib 3Docetaxel 3Biopsy 3pembrolizumab 2olaparib 2liposomal doxorubicin 2Vincristine 2Trastuzumab 2Trabectedin 2Temozolomide 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2Proton Therapy 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ifosfamide 2Filgrastim 2Etoposide 2Drug Therapy 2Doxorubicin 2Celecoxib 2Carboplatin 2Ascorbic Acid 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2trastuzumab biosimilar HLX02 1tozuleristide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Sarcoma × Bevacizumab × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡